-
Pfizer Should Outperform, Morgan Stanley Upgrades
Wednesday, September 20, 2017 - 9:45am | 395Analysts at Morgan Stanley turned bullish on Pfizer Inc. (NYSE: PFE) amid multiple catalysts and accretive M&A opportunities ahead. Analyst David Risinger upgraded Pfizer's stock from Equal-weight to Overweight with a price target boosted from $35 to $39. Ibrance Pfizer's pipeline is...